Compare Globus Medical Inc. Class A Common Stock (GMED) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Global X NASDAQ 100 Covered Call ETF trades at $18.64 (market cap $8.54B). The key difference: Globus Medical Inc. Class A Common Stock is the larger of the two by market cap, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Global X NASDAQ 100 Covered Call ETF for 51 Days on average.
| GMED | QYLD | |
|---|---|---|
Market Cap | $10.25B | $8.54B |
Volume | 1,108,124 | 2,383,712 |
Sector | Health | Income / Options Overlay |
52-Week High | $96.82 | $18.69 |
52-Week Low | $58.33 | $16.70 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
QYLD trades at $18.69, showing minimal daily movement with a 0.05% gain. The ETF's technical outlook is bullish based on moving averages, but oscillators signal caution with RSI levels above 75 indicating overbought conditions. Recent news highlights its high monthly dividend yield but raises concerns about long-term capital erosion and capped upside due to its covered call strategy, with distributions consistently at $0.18 per share.
The outlook for QYLD is mixed; it offers attractive income with a high yield, appealing for investors seeking monthly cash flow. However, risks include limited growth potential, declining option premiums, and potential tax reclassification of dividends. Analyst sentiment is divided, with some upgrades citing yield attractiveness but others warning of principal erosion over time.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
